Pulsing depression

The dozens of depression drugs on the market are of no help to millions of patients due to lack of efficacy or intolerable side effects. Neuronetics Inc. is targeting these patients with its NeuroStar device, which was approved by FDA last October to treat major depressive disorder in patients who have failed one prior antidepressant after reaching the minimal effective dose and duration.

On the heels of a $30 million series D round late last month, the company will now set about increasing sales and leases of the device, as well as conducting trials to expand its approved indications...